Clinical Observation On Xinnaoning Capsule In Intervention Of Post-ACS Status And High-sensitivity C-reactive Protei

Purpose:Through clinical observation of the intervention effect of Xinnaoning capsule on angina pectoris symptoms and hypersensitive C-reactive protein in patients with acute coronary syndrome in the later stage,it provides a new reference for clinical treatmentMaterial and method: This study selected 70 patients who met the inclusion and exclusion criteria and were hospitalized in the Department of Cardiology or Professor Zhang Yan of the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine from December 2020 to December 2021.The trial adopted the method of central randomization,double-blind and placebo control.The subjects were randomly divided into treatment group and control group,with 35 patients in each group.The patients in the control group were given basic western medicine treatment.The treatment group was given Xinnaoning capsule on the basis of the control group,and 4 weeks of standard clinical treatment was a course of treatment,The treatment lasted for 24 weeks for 6 courses.Nitroglycerin withdrawal rate,total myocardial ischemia load(TIB),Seattle angina pectoris scale(SAQ),and hypersensitive C-reactive protein(hs-CRP)were recorded before and after treatment.SPSS27.0 statistical software was used to process the collected data,and intra-group and inter-group comparisons were made to evaluate the clinical effectiveness.Results:(1)At the time of enrollment,the baseline data and various outcome indicators of the two groups were compared between the two groups(P>0.05),and there was no significant statistical difference between the two groups;(2)After the treatment of total myocardial ischemia load,the two groups were significantly improved(P<0.01),but the decrease was more obvious in the test group.The difference between the two groups was significant(P<0.01);(3)The rate of nitroglycerin stopping and reducing,the efficacy of the test group was better than that of the control group after treatment,and the difference between the two groups was significant(P<0.05).(4)After treatment,the hypersensitive C-reactive protein in both groups decreased significantly(P<0.01),but the effect of the test group was better,and the difference between the two groups was significant(P<0.01);(5)The scores of the two groups were improved before and after treatment,but the effect of the test group was more significant.After treatment,there were significant differences between the two groups(P<0.01).Conclusion:Xinnaoning can improve and alleviate patients’ angina symptoms,reduce the level of inflammatory factors,and improve the quality of life of patients after acute coronary syndrome with fewer adverse effects,providing a new idea for clinicians to treat such diseases.